SavedAdd your journal

Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Volume: 46 Issue: 3

Strategies to Enhance the Solubility and Oral Bioavailability of Furosemid: A Review

Ahmad Ainurofiq(Universitas Sebelas Maret)0000-0003-2880-5321
Khusnul Ergina Reswari(Universitas Sebelas Maret)0009-0000-3869-2215
Nur Aida Latifah Azzahro(Universitas Sebelas Maret)0009-0008-2439-1305
Revina Syuraanantya(Universitas Sebelas Maret)0009-0009-4773-9244
Alfian Hakim Restu Putra(Universitas Sebelas Maret)0009-0006-4203-5246
Shabrina Syaharani(Universitas Sebelas Maret)0009-0002-7479-0941
Levinahansa Arbelinda(Universitas Sebelas Maret)0009-0003-9575-8892
Pages
—
Publication Date
2026-09-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, physicochemical modification and nanotechnology-based preformulation strategies offer promising potential to overcome the solubility limitations of furosemide, thereby improving oral therapeutic efficacy and reducing interindividual pharmacokinetic variability.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Furosemide is a loop diuretic widely prescribed for the management of edema and hypertension; however, its oral efficacy is limited by poor solubility and low permeability.
📊
Key Findings & Data:According to the Biopharmaceutics Classification System, furosemide belongs to class IV, necessitating optimization at the preformulation stage to enhance its biopharmaceutical performance.
💡
Conclusion & Impact:Overall, physicochemical modification and nanotechnology-based preformulation strategies offer promising potential to overcome the solubility limitations of furosemide, thereby improving oral therapeutic efficacy and reducing interindividual pharmacokinetic variability.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Furosemide · nanotechnology · preformulation

Abstract

Furosemide is a loop diuretic widely prescribed for the management of edema and hypertension; however, its oral efficacy is limited by poor solubility and low permeability. According to the Biopharmaceutics Classification System, furosemide belongs to class IV, necessitating optimization at the preformulation stage to enhance its biopharmaceutical performance. This review aims to analyze various preformulation strategies that have been demonstrated to improve the solubility and oral bioavailability of furosemide through an extensive literature review of scientific publications from the past decade. The investigated approaches include particle size reduction, co-amorphous systems, micronization, solid dispersion, solvent evaporation, cyclodextrin complexation, pH adjustment, self-nanoemulsifying drug delivery systems, nanostructured lipid carriers, solid–liquid nanoparticles, nanosuspensions, and controlled precipitation methods. The review indicates that these strategies markedly enhance the dissolution rate and physical stability of furosemide through several mechanisms, such as increased surface area, amorphous phase formation, inclusion complexation, and maintenance of supersaturated states. Among the reviewed strategies, lipid-based and nanoscale delivery systems generally demonstrated greater improvements in oral bioavailability than conventional approaches, although direct comparisons should be interpreted with caution because of differences in study design, experimental conditions, and pharmacokinetic endpoints. Overall, physicochemical modification and nanotechnology-based preformulation strategies offer promising potential to overcome the solubility limitations of furosemide, thereby improving oral therapeutic efficacy and reducing interindividual pharmacokinetic variability.

🔖

Cite This Article

Ainurofiq, A., Reswari, K. E., Azzahro, N. A. L., Syuraanantya, R., Putra, A. H. R., Syaharani, S., Arbelinda, L. (2026). Strategies to Enhance the Solubility and Oral Bioavailability of Furosemid: A Review. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Volume: 46 Issue: 3. https://doi.org/10.52794/hujpharm.1830543

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (36)

  1. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020 Mar 17;75[10]:1178–95. doi:10.1016/j.jacc.2019.12.059
  2. Khan TM, Patel R, Siddiqui AH. Furosemide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Sep 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK499921/
  3. Rasmussen JE, Lundström P, Eriksson PO, Rask-Andersen H, Liu W, Laurell G. The acute effects of furosemide on Na-K-Cl cotransporter-1, fetuin-A and pigment epithelium-derived factor in the guinea pig cochlea. Front Mol Neurosci. 2022 Mar 22;15:842132. doi:10.3389/fnmol.2022.842132
  4. Gul S, Sridhar SB, Jalil A, Akhlaq M, Arshad MS, Sarwar HS, et al. Solid self-nanoemulsifying drug delivery systems of furosemide: in vivo proof of concept for enhanced predictable therapeutic response. Pharmaceuticals. 2024 Apr 14;17[4]:500. doi:10.3390/ph17040500
  5. Choudhury H, Gorain B, Madheswaran T, Pandey M, Kesharwani P, Tekade RK. Drug Complexation: Implications in Drug Solubilization and Oral Bioavailability Enhancement. Implications in Drug Solubilization and Oral Bioavailability Enhancement. In: Dosage Form Design Considerations: Volume I. 2018. p. 473–512. doi:10.1016/B978-0-12-814423-7.00014-9
  6. Csicsák D, Szolláth R, Kádár S, Ambrus R, Bartos C, Balogh E, et al. The effect of the particle size reduction on the biorelevant solubility and dissolution of poorly soluble drugs with different acid-base character. Pharmaceutics. 2023;15[1]. doi:10.3390/pharmaceutics15010278
  7. Elmubarak EH, Osman ZA, Abdelrahman M. Formulation and evaluation of solid dispersion tablets of furosemide using polyvinylpyrrolidone K-30. Int J Curr Pharm Res. 2021 Mar 15;43–50. doi:10.22159/ijcpr.2021v13i2.41554
  8. Ruponen M, Kettunen K, Santiago Pires M, Laitinen R. Co-amorphous formulations of furosemide with arginine and P-Glycoprotein inhibitor drugs. Pharmaceutics. 2021 Jan 27;13[2]:171. doi:10.3390/pharmaceutics13020171
  9. Markovic M, Zur M, Ragatsky I, Cvijić S, Dahan A. BCS class IV oral drugs and absorption windows: Regional-dependent intestinal permeability of furosemide. Pharmaceutics. 2020 Dec 2;12[12]:1175. doi:10.3390/pharmaceutics12121175
  10. Osmanska J, Petrie MC, Docherty KF, Lee MMY, McMurray JJV, Campbell RT. Subcutaneous furosemide in heart failure: A systematic review. Eur Heart J - Cardiovasc Pharmacother. 2025 Feb 8;11[1]:94–104. doi:10.1093/ehjcvp/pvae083
  11. Babu BVS, Prajapati MK. Advanced strategies for enhancing bioavailability using SNEDDS: Formulation design, mechanism, and applications. J Drug Deliv Sci Technol. 2026;121. doi:10.1016/j.jddst.2026.108364
  12. Al-Shdefat RI. Enhanced diuretic action of furosemide by complexation with β-cyclodextrin in the presence of sodium lauryl sulfate. Green Process Synth. 2020 Dec 15;9[1]:744–50. doi:10.1515/gps-2020-0069
  13. İnal TG, Öztürk N, Kara A, Şahin S, Vural İ. Effect of precipitation inhibitors on supersaturation and solubility of furosemide. J Res Pharm. 2025 Jun;25[2]:209–17. doi:10.29228/jrp.11
  14. Garnero C, Chattah AK, Longhi M. Stability of furosemide polymorphs and the effects of complex formation with β-cyclodextrin and maltodextrin. Carbohydr Polym. 2016;152:598–604. doi:https://doi.org/10.1016/j.carbpol.2016.07.006
  15. Alshora D, Alyousef W, Ibrahim M. Effects of functional biomaterials on the attributes of orally disintegrating tablets loaded with furosemide nanoparticles: In vitro and in vivo evaluations. J Funct Biomater. 2024 Jun 9;15[6]:161. doi:10.3390/jfb15060161
  16. Ali H, Singh SK. Preparation and characterization of solid lipid nanoparticles of furosemide using quality by design. Part Sci Technol. 2018;36[6]:695–709. Located at: Scopus. doi:10.1080/02726351.2017.1295293
  17. Nagai N, Ogata F, Kadowaki R, Deguchi S, Otake H, Nakazawa Y, et al. Design of an oral tablet containing furosemide nanoparticles with elevated bioavailability. J Oleo Sci. 2024;73[4]:563–71. doi:10.5650/jos.ess23229
  18. Ilyas M, Rehman Asim ur., Tayyab M, Nawaz Malik M, Ahmed N, Fatima H. Box–Behnken based furosemide-nanostructured lipid carriers (NLCs) delivery system for improving oral bioavailability. Drug Dev Ind Pharm. 2025 Mar 4;51[3]:219–30. doi:10.1080/03639045.2025.2460062
  19. Sahu BP, Das MK. Formulation, optimization, and in vitro/in vivo evaluation of furosemide nanosuspension for enhancement of its oral bioavailability. J Nanoparticle Res. 2014;16[4]. doi:10.1007/s11051-014-2360-z
  20. Wu W, Löbmann K, Rades T, Grohganz H. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems. Int J Pharm. 2018;535(1–2):86–94. doi:10.1016/j.ijpharm.2017.10.057
  21. Wang H, Liu J, Fan X, Ren J, Liu Q, Kong B. Fabrication, characterisation, and application of green crosslinked sodium alginate hydrogel films by natural crab-shell powders to achieve drug sustained release. LWT. 2022 Dec;171:114147. doi:10.1016/j.lwt.2022.114147
  22. Mohammed-Kadhum MF, Hameed GS. Development and characterization of furosemide-loaded binary amorphous solid dispersion to enhance solubility and dissolution for pediatric oral administration. Pharmacia. 2025 Jul 4;72:1–19. doi:10.3897/pharmacia.72.e156784
  23. Patel RP, Patel DJ, Bhimani DB, Patel JK. Physicochemical characterization and dissolution study of solid dispersions of furosemide with polyethylene glycol 6000 and polyvinylpyrrolidone k30. Dissolution Technol. 2008;15[3]:17–25. doi:10.14227/DT150308P17
  24. Diniz LF, Carvalho PS, Pena SAC, Gonçalves JE, Souza MAC, de Souza Filho JD, et al. Enhancing the solubility and permeability of the diuretic drug furosemide via multicomponent crystal forms. Int J Pharm. 2020 Sep 25;587:119694. doi:10.1016/j.ijpharm.2020.119694
  25. Saeed MA, Ansari MT, Ch BA. Enhancement of solubility and dissolution profile of artesunate by employing solid dispersion approach: An in-vitro evaluation. Pak J Pharm Sci. 2019;32[1]:353–61.
  26. Abraham-Miranda J, Garnero C, Zoppi A, Chattah AK, Sterren VB, Santiago de Oliveira Y, et al. Evaluating ternary systems with oligosaccharides as a strategy to improve the biopharmaceutical properties of furosemide. Mater Sci Eng C. 2020;111. doi:10.1016/j.msec.2020.110793
  27. Li H, Sun J, Wang Y, Sui X, Sun L, Zhang J, et al. Structure-based in silico model profiles the binding constant of poorly soluble drugs with β-cyclodextrin. Eur J Pharm Sci. 2011;42(1–2):55–64. doi:10.1016/j.ejps.2010.10.006
  28. Medina-López R, Guillén-Moedano S, Hurtado M. In vitro release studies of furosemide reference tablets: influence of agitation rate, USP apparatus and dissolution media. ADMET DMPK. 2020 Jun 29. doi:10.5599/admet.801
  29. Dalal L, Allaf AW, El-Zein H. Formulation and in vitro evaluation of self-nanoemulsifying liquisolid tablets of furosemide. Sci Rep. 2021 Jan 14;11[1]:1315. doi:10.1038/s41598-020-79940-5
  30. Fathi HA, Yousry C, Elsabahy M, El-Badry M, El Gazayerly ON. Effective loading of incompatible drugs into nanosized vesicles: a strategy to allow concurrent administration of furosemide and midazolam in simulated clinical settings. Int J Pharm. 2023 Apr 5;636:122852. doi:10.1016/j.ijpharm.2023.122852
  31. Shariare MH, Altamimi MA, Marzan AL, Tabassum R, Jahan B, Reza HM, et al. In vitro dissolution and bioavailability study of furosemide nanosuspension prepared using design of experiment (DoE). Saudi Pharm J. 2019 Jan 1;27[1]:96–105. doi:10.1016/j.jsps.2018.09.002
  32. Korni RD, Gonugunta CSR. Olanzapine liquisolid tablets using Kolliphor EL with improved flowability and bioavailability: In vitro and in vivo characterization. Turk J Pharm Sci. 2024;21[1]:52–61. doi:10.4274/tjps.galenos.2023.05752
  33. Zhang F, Mao J, Tian G, Jiang H, Jin Q. Preparation and characterization of furosemide solid dispersion with enhanced solubility and bioavailability. AAPS PharmSciTech. 2022;23[1]. doi:10.1208/s12249-022-02208-w
  34. Wang M, Gong J, Rades T, Martins ICB. Amorphization of different furosemide polymorphic forms during ball milling: Tracking solid-to-solid phase transformations. Int J Pharm. 2023 Dec 15;648:123573. doi:10.1016/j.ijpharm.2023.123573
  35. Khan S, Sharma A, Jain V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv Pharm Bull. 2023 Jul;13[3]:446–60. doi:10.34172/apb.2023.056
  36. López KL, Ravasio A, González-Aramundiz JV, Zacconi FC. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) prepared by microwave and ultrasound-assisted synthesis: Promising green strategies for the nanoworld. Pharmaceutics. 2023 Apr 25;15[5]:1333. doi:10.3390/pharmaceutics15051333